Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

MPN Congress 2022 | Fibrotic progression of ET and PV: clinical and biological considerations

Raajit Rampal • 24 Nov 2022
MPN Congress 2022
Essential Thrombocythemia Myeloproliferative Neoplasms Polycythemia Vera Rare Diseases

Raajit Rampal, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, gives a presentation on the clinical and biological considerations for fibrotic progression in essential thrombocythemia (ET) and polycythemia vera (PV) at the 14th International Congress on Myeloproliferative Neoplasms (MPNs) held in New York City, NY.

More from Raajit Rampal

Interferon in PV and ET: unanswered questions
0:45
Interferon in PV and ET: unanswered questions
Raajit Rampal • 24 Aug 2024
The evolving treatment landscape in PV
0:56
The evolving treatment landscape in PV
Raajit Rampal • 24 Aug 2024
TP53 mutation in MPNs and investigating LSD1 inhibition in TP53-mutant murine models
1:27
TP53 mutation in MPNs and investigating LSD1 inhibition in TP53-mutant murine models
Raajit Rampal • 24 Aug 2024
Novel agents under investigation in MPNs: MDM2, XPO1, and BET inhibitors
0:34
Novel agents under investigation in MPNs: MDM2, XPO1, and BET inhibitors
Raajit Rampal • 14 Jun 2024

Related Videos

Federated learning to train generative AI models for diagnosis & prognosis of hematological diseases
2:08
Federated learning to train generative AI models for diagnosis & prognosis of hematological diseases
Raajit Rampal • 7 Dec 2025
Guidance for selecting between JAK inhibitors in the frontline and second-line setting for MF
1:26
Guidance for selecting between JAK inhibitors in the frontline and second-line setting for MF
Raajit Rampal • 6 Dec 2025
An overview of ongoing Phase III trials investigating novel treatment options for myelofibrosis
1:40
An overview of ongoing Phase III trials investigating novel treatment options for myelofibrosis
Raajit Rampal • 6 Dec 2025
The management of patients with ET or PV during pregnancy
3:32
The management of patients with ET or PV during pregnancy
Raajit Rampal • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals